Loading
Spanish immunologist who pioneered CD137 agonist antibodies and intratumoural immunotherapy.
Ignacio Melero showed in 1997 that agonist antibodies to CD137 (4-1BB) eradicate established tumours in mice, founding the field of costimulatory agonist immunotherapy, and has led early-phase trials of CD137 agonists, intratumoural immunostimulants and combination immunotherapy in liver cancer. He co-authored the CheckMate 040 nivolumab studies in hepatocellular carcinoma and leads immunotherapy research at CIMA and Clínica Universidad de Navarra.
| Title | Journal | Year |
|---|---|---|
| Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors | Nature Medicine | 1997 |
| Intratumoural administration and tumour tissue targeting of cancer immunotherapies | Nature Reviews Clinical Oncology | 2021 |
Shares Cancer Center Clínica Universidad de Navarra / CIMA, Hepatocellular carcinoma and the tag immunotherapy.
Shares Nivolumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Nivolumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Nivolumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Nivolumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Nivolumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Nivolumab, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Nivolumab, Immune checkpoint inhibitors and the tag immunotherapy.